'GenesisCare Murdoch'
Welcome,         Profile    Billing    Logout  
 1 Trial 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chen, Tina
PROSTACT, NCT04876651: The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only

Recruiting
3
392
RoW
177Lu-DOTA-rosopatamb, 177Lu-TLX591, Standard of Care
Telix Pharmaceuticals (Innovations) Pty Ltd
Metastatic Prostate Cancer
11/25
12/28
PRIMARY2, NCT05154162: PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI

Recruiting
3
660
RoW
PSMA PET/CT, Transperineal template prostate biopsy, Transperineal targeted prostate biopsy
Peter MacCallum Cancer Centre, Australia, St Vincent's Hospital, Sydney
Prostate Cancer
03/27
03/28
iPREDICT, NCT05013099 / 2021-005610-33: Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies

Active, not recruiting
2
70
Europe, US, RoW
zirconium Zr 89 crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C
ImaginAb, Inc.
Melanoma, Merkel Cell Carcinoma, Unspecified, Renal Cell Carcinoma, Non Small Cell Lung Cancer
07/25
07/25
NCT04721756: Early Clinical Evaluation of 18F-LY3546117 in Tumor Imaging

Recruiting
1
30
RoW
18F-LY3546117 Injection, PET Scan
Avid Radiopharmaceuticals
Neoplasms, Neoplasms Malignant
04/24
04/24

Download Options